Pasithea Therapeutics Corp. (KTTA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pasithea Therapeutics Corp. (KTTA) Healthcare & Pipeline Overview

Pasithea Therapeutics Corp. (KTTA) is a biotechnology firm specializing in psychiatric and neurological disorder treatments, including potential ketamine infusion clinics. Incorporated in 2020, the company operates with a small team, focusing on research and discovery within the competitive healthcare landscape, but currently carries a medium risk profile.

What Is the Investment Thesis for KTTA?

Pasithea Therapeutics Corp. presents a high-risk, high-reward investment opportunity in the biotechnology sector. The company's focus on psychiatric and neurological disorders, coupled with its planned ketamine infusion clinics, offers potential for significant growth if clinical trials and regulatory approvals are successful. However, with a market capitalization of approximately $10 million and a small team, the company faces substantial execution risks. Key value drivers include successful development and commercialization of novel therapies, expansion of clinic operations, and strategic partnerships. The company's beta of 0.22 suggests lower volatility compared to the overall market, but this may not fully reflect the inherent risks of early-stage biotech companies. Investors should carefully consider the company's financial position, regulatory hurdles, and competitive landscape before investing.

Based on FMP financials and quantitative analysis

KTTA Key Highlights

Pasithea Therapeutics Corp. focuses on research and discovery of treatments for psychiatric and neurological disorders.

• The company intends to operate anti-depression clinics administering intravenous infusions of ketamine.
• Incorporated in 2020, Pasithea is still in its early stages of development.
• The company is headquartered in Miami Beach, Florida.
• Pasithea has a small team of 4 employees, managed by CEO Tiago Reis Marques.

Who Are KTTA's Competitors?

KTTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KTTA's Key Strengths?

Focus on a growing market for mental health treatments.

• Potential for innovative therapies and clinical services.
• Experienced management team.
• Strategic location in Miami Beach, Florida.

What Are KTTA's Weaknesses?

Small size and limited resources.

• Early stage of development with no approved products.
• Reliance on ketamine infusions, which may face regulatory challenges.
• High risk of clinical trial failures.

What Could Drive KTTA Stock Higher?

Clinical trial results for novel therapies targeting psychiatric and neurological disorders.

• Regulatory approvals for ketamine infusion clinics in new locations.
• Expansion of the company's research and development pipeline.
• Strategic partnerships and collaborations with other biotechnology companies.

What Are the Key Risks for KTTA?

Negative return on equity (-57.4%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and delays in regulatory approvals.
• Competition from larger, more established pharmaceutical companies.
• Regulatory changes affecting the use of ketamine.
• Limited financial resources and potential need for additional funding.

What Are the Growth Opportunities for KTTA?

• Expansion of Ketamine Clinic Network: Pasithea has the opportunity to expand its network of anti-depression clinics offering ketamine infusions. The market for ketamine treatments is growing, driven by its rapid antidepressant effects and potential for treating treatment-resistant depression. The company could establish new clinics in underserved areas or partner with existing healthcare providers to offer ketamine services. Success depends on regulatory approvals, physician acceptance, and patient demand. The market size for ketamine treatments is projected to reach $1 billion by 2028, offering substantial growth potential for Pasithea.
• Development of Novel Therapies: Pasithea can leverage its research and discovery capabilities to develop novel therapies for psychiatric and neurological disorders. This includes identifying new drug targets, conducting preclinical and clinical trials, and seeking regulatory approvals for innovative treatments. The market for novel therapies is substantial, driven by unmet needs in mental health and advancements in neuroscience. Success depends on scientific breakthroughs, clinical trial outcomes, and regulatory approvals. The global market for psychiatric drugs is projected to reach $150 billion by 2027, providing a significant opportunity for Pasithea.
• Strategic Partnerships and Collaborations: Pasithea can pursue strategic partnerships and collaborations with other biotechnology companies, pharmaceutical firms, and academic institutions. This includes licensing agreements, joint ventures, and research collaborations. Partnerships can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of Pasithea's therapies. The market for biotech partnerships is active, with numerous deals occurring each year. Success depends on identifying suitable partners and negotiating favorable terms. Strategic alliances can significantly enhance Pasithea's growth prospects.
• Geographic Expansion: Pasithea has the potential to expand its operations geographically, both within the United States and internationally. This includes establishing new clinics, conducting clinical trials in different regions, and seeking regulatory approvals in new markets. Geographic expansion can provide access to new patient populations and revenue streams. Success depends on understanding local market dynamics, navigating regulatory requirements, and building relationships with healthcare providers. The global market for mental health treatments is expanding, offering opportunities for Pasithea to establish a presence in new regions.
• Integration of Digital Health Technologies: Pasithea can integrate digital health technologies into its clinical services and research programs. This includes using mobile apps, wearable devices, and telehealth platforms to monitor patients, collect data, and deliver remote care. Digital health technologies can improve patient engagement, enhance treatment outcomes, and reduce healthcare costs. The market for digital health is growing rapidly, driven by increasing adoption of telehealth and mobile health solutions. Success depends on developing user-friendly technologies, ensuring data privacy and security, and integrating digital health into clinical workflows.

What Are KTTA's Competitive Advantages?

• Proprietary research and development capabilities in psychiatric and neurological disorders.
• Potential for intellectual property protection through patents and trademarks.
• First-mover advantage in operating ketamine infusion clinics.
• Expertise in administering ketamine infusions using trained pharmacists.

What Does KTTA Do?

Pasithea Therapeutics Corp., established in 2020 and headquartered in Miami Beach, Florida, is a biotechnology company dedicated to the research and discovery of innovative treatments for psychiatric and neurological disorders. The company's strategic focus involves developing therapies to address unmet needs in mental health, leveraging scientific advancements to improve patient outcomes. Pasithea's business model includes the planned operation of anti-depression clinics, where trained pharmacists will administer intravenous infusions of ketamine, a treatment showing promise for certain depressive conditions. This dual approach of drug discovery and clinical service delivery positions Pasithea uniquely within the biotechnology sector. The company's relatively small size, with only four employees, reflects its early stage of development and emphasis on focused research initiatives. Pasithea aims to contribute significantly to the evolving landscape of mental health treatment through its targeted therapeutic programs and clinical services.

What Products and Services Does KTTA Offer?

• Engages in research and discovery of treatments for psychiatric disorders.
• Focuses on developing treatments for neurological disorders.
• Plans to operate anti-depression clinics.
• Provides business support services.
• Administers intravenous infusions of ketamine using trained pharmacists.
• Aims to address unmet needs in mental health treatment.

How Does KTTA Make Money?

• Develops and commercializes treatments for psychiatric and neurological disorders.
• Operates anti-depression clinics providing ketamine infusions.
• Generates revenue through clinic services and potential future drug sales.
• May pursue partnerships and licensing agreements to generate additional revenue.

What Industry Does KTTA Operate In?

Pasithea Therapeutics Corp. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for psychiatric and neurological disorder treatments is substantial and growing, driven by increasing prevalence of mental health conditions and advancements in neuroscience. Key trends include the development of personalized medicine, the use of digital health technologies, and the integration of mental health services with primary care. Pasithea's focus on ketamine infusions and novel therapies positions it within the evolving landscape of mental health treatment, but it faces competition from larger, more established pharmaceutical companies and other biotechnology firms.

Who Are KTTA's Key Customers?

• Patients suffering from psychiatric disorders such as depression and anxiety.
• Patients with neurological disorders.
• Healthcare providers seeking innovative treatment options.
• Potential partners and licensees in the biotechnology and pharmaceutical industries.

Company Profile

Pasithea Therapeutics Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Tiago Reis Marques. KTTA has traded publicly since 2021.

Return on equity for Pasithea Therapeutics Corp. stands at -57.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.0%, showing how much profit it generates from its asset base. A current ratio of 35.40 indicates the company holds enough short-term assets to cover its near-term obligations.

KTTA Valuation & Market Position

Analyst price targets span from $3.00 to $3.00, with a consensus of $3.00. At the current price of $0.54, that implies approximately 456% upside potential. Relative to its peer group, KTTA's quantitative score of 44/100 is below the peer average of 88/100.

Quarterly Financial Performance: Pasithea Therapeutics Corp.

Revenue for Pasithea Therapeutics Corp. came in at $0 during Q2 FY2026. The company recorded a net loss of $5.3M, with diluted EPS of $-0.75. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, KTTA averaged $-0.75 in diluted EPS.

Pasithea Therapeutics Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.54 places it in the safe zone, indicating low near-term bankruptcy risk.

Pasithea Therapeutics Corp. has missed Wall Street's EPS estimate in 2 of its last 4 reported quarters — a mixed record worth weighing. Reported results have landed about 112.2% below estimates on average.

Over the past six months, Pasithea Therapeutics Corp. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 4.7M shares acquired (about $3.9M) — insiders putting money in tends to read as conviction.

KTTA Financials

KTTA Latest News

KTTA Analyst Consensus

KTTA MoonshotScore

Common Questions About KTTA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources